Table 1.
Characteristics of patients with nonfunctional pancreatic neuroendocrine neoplasms and outcome of their surveillance strategy
| Author (year) | Number of Patients | Median follow up | Median tumor size at enrollment (mm) | Number of tumors with growth (%) | Patients with FN metastases | Patients with liver metastases | Patients who underwent surgery (%) | Reason for surgery |
|---|---|---|---|---|---|---|---|---|
| Lee et al., 2012[21] | 77 | Mean 35 (3-153) | 10 (3-32) | NS | 0 | 0 | 2 (3) | 1 MPD dilation 1 Unclear reason |
| Gaujoux et al., 2013[22] | 46 | 34 (IQR 24-53) | 13 (9-15) | 12 (26) | 0 | 0 | 8 (17) | 5 Patient’s choice 3 Tumor growth |
| Crippa et al., 2014[23] | 12 | 36 (18-66) | 14 (10-29) | 0 | 0 | 0 | None | |
| Kishi et al., 2014[24] | 19 | 45 (19-162) | 12 (6-33) | 4 (20) | 0 | 0 | 1 (5) | Tumor growth |
| Rosenberg et al., 2015[25] | 15 | NS | 14 (8-110) | 0 | 0 | 3 (20%)^ | 0 | None |
| Jung et al., 2015[26] | 85 | Mean 31.5 | 11.4 (4-20) | 15 (17.6) | 0 | 0 | 12 (14.1) | 8 Tumor growth 3 Patient’s choice 1 Development of symptoms |
| Sadot et al., 2016[27] | 104 | 44 (4-223) | 12 (IQR 8-17) | 53 (51) | 0 | 0 | 26 (25) | 10 Patient’s choice 8 Tumor growth 7 Physician’s choice 1 MPD dilatation |
^Primary tumors were all >2 cm, NS: Not stated, MPD: Main pancreatic duct, IQR: Interquartile range